SOURCE: Sirona Biochem Corp.

Sirona Biochem Corp.

April 13, 2015 08:00 ET

Sirona Biochem to Present at BioNetwork East -- May 2015

VANCOUVER, BC--(Marketwired - April 13, 2015) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BioNetwork East on May 4th, 2015 at the Trump International Beach Resort in Miami Florida.

BioNetwork East has become one of the top partnering events for Pharma and Biotech companies in North America. The conference provides a more intimate, informal setting, allowing attendees to meet everyone and interact with one another.

Sirona will have the opportunity to showcase the latest results to a range of pharmaceutical and biotech professionals. Big pharma attendees include: Bayer Healthcare, AstraZeneca, Amgen, BMS, Pfizer, Eli Lilly, Kowa Pharmaceuticals and Merck.

About BioNetwork East

Since 2003 BioNetwork has been providing the essential platform for business development executives across the pharmaceutical and biotechnology space to efficiently come together in an intimate setting and develop relationships that lead to strategic partnerships. For more information, please visit www.bionetworkeast.wbresearch.com.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Contact Information

  • For more information regarding this press release, contact:

    Christopher Hopton
    CFO
    Sirona Biochem Corp.
    Phone: 1.604.282.6064
    Email: chopton@sironabiochem.com